Analyst firms · Guggenheim · INCY
Guggenheim INCY price target and rating history
Incyte Corp. (INCY) · Health Care
Guggenheim rates Incyte Corp. (INCY) Buy with a $125 price target, as of its latest action on Nov 3, 2025. It has published 4 rating actions on INCY since August 2022, including 2 upgrades and 2 downgrades. Across 9 firms with a INCY price target in the last 12 months, the median target is $119.
- Current rating
- Buy
- Price target
- $125
- Median target, all firms
- $119
- Actions on INCY
- 4
Guggenheim price target on INCY
Every Guggenheim rating on INCY
- Nov 3, 2025
- Mar 18, 2025
- Dec 4, 2023
- Aug 3, 2022
How other firms rate INCY
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Oppenheimer | Outperform | $144 | Oct 30, 2026 |
| Morgan Stanley | Equal-Weight | $119 | Oct 20, 2026 |
| Canaccord Genuity | Buy | $152 | Aug 20, 2026 |
| BMO Capital Markets | Market Perform | $94 | Jun 22, 2026 |
| Bernstein | Mkt Perform | $99 | May 22, 2026 |
| Jefferies | Hold | $94 | Mar 16, 2026 |
| H.C. Wainwright | Buy | $135 | Feb 5, 2026 |
| Wells Fargo | Equal Weight | $107 | Jan 20, 2026 |
| Mizuho | Outperform | $121 | Dec 8, 2025 |
Questions about Guggenheim and INCY
- What is Guggenheim's price target for INCY?
- Guggenheim's latest stated price target for Incyte Corp. (INCY) is $125, from its action on Nov 3, 2025.
- What is Guggenheim's rating on INCY?
- Guggenheim rates INCY Buy, a bullish rating, as of Nov 3, 2025.
- When did Guggenheim last change its view on INCY?
- On Nov 3, 2025, Guggenheim upgrades to Buy from Neutral, price target $125.
- How does Guggenheim's INCY target compare with other analysts?
- Across 9 firms with a INCY price target in the last 12 months, the median target is $119.
More INCY rating histories
All Guggenheim ratingsINCY news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.